Where would you be and what would you be doing tomorrow, February 14 , 2025 Valentine’s Day? Painting the town red or just watching the world go by?My boosts long hung and other Valentine ...

An overall increase in life expectancy was observed across all individuals living with HIV but disparities between gender groups persist.

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

The UK government has announced that it is renewing funding for the public health campaign HIV Prevention England for another year as part of efforts to end HIV transmission by 2030. The programme, ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...

Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the ...

Preexposure prophylaxis, known as PrEP, reduces the risk of new HIV infections through sex by 99% and among injectable drug ...

HIV infections have been falling in recent years, with just 1.3 million new cases recorded in 2023, a 60 per cent decline since the virus peaked in 1995.

Donald Trump's decision to cut vital aid has stunned health officials and charities working to fight HIV and AIDS. One told ...

Between 2001 and 2024, USD 9.74 billion (Sh1.25 trillion) has been disbursed to Kenya through USAID which represents 68.33 ...